Your Retirement Is at Risk Here’s How to Protect It

Hey there, bargain hunter. Evonik closed Monday (September 28, 2026) at €19.84. BASF’s opening bid is €22.15. The board said no. You are sitting in a €2.31 gap that either closes toward a sweeter offer, widens toward €18 if the deal dies, or does something stranger still. Let’s figure out which is most likely.

Scoreboard

BASF offered about €22.15 per Evonik share. Evonik’s stock, which closed at €18.07 on Thursday (September 24, 2026) before news of the approach, ended Monday up 2.4% at €19.84. BASF shares were down 3.6% on Friday (September 25, 2026), when BASF confirmed it was in exploratory talks. The market is pricing roughly a 60% chance the deal happens at something above €22.15, and a 40% chance BASF walks. That arithmetic is in the spread.

What Actually Happened

Evonik declined BASF’s €10.3 billion takeover bid, citing the offer as insufficient to warrant formal negotiations or due diligence. This is a familiar takeover script: the buyer points to synergies while the target wants a clearer price before engaging. BASF has argued those synergies can only be confirmed if Evonik cooperates, which gives it a reason not to bid higher until it gets deeper access to Evonik’s numbers.

The proposed price represented a nearly 29% premium to Evonik’s stock prior to public speculation, assigning the target an enterprise value of approximately €14.2 billion. The board called that insufficient. They may be right.

What the Business Is Worth Standing Alone

Evonik operates as a specialty chemicals company with a portfolio spanning additives, polymers, catalysts, and nutrition products, selling into end markets that include automotive, pharmaceuticals, and personal care. Evonik posted 2025 sales of €14.1 billion and adjusted EBITDA of about €1.9 billion.

The business is mid-turnaround and accelerating. CEO Christian Kullmann called Q2 2026 “the best quarter result in four years.” Adjusted EBITDA surged 24% year-over-year to €630 million, and Evonik raised its full-year outlook to adjusted EBITDA of €2.0 billion to €2.2 billion, up from €1.7 billion to €2.0 billion.

Key Numbers

• 2025 Sales: €14.1 billion
• 2025 Adjusted EBITDA: about €1.9 billion
• 2026 EBITDA Guidance (raised): €2.0 billion to €2.2 billion
• 2025 Free Cash Flow: €695 million on a cash conversion rate of 37%
• 2026 Cash Conversion Target: ~40%
• Restructuring: workforce reductions totaling about 2,800 roles over 2024 to 2026 under the efficiency program Evonik has described publicly

BASF generated sales of about €59.7 billion in 2025. A combined entity would be bigger, but the “global ranking” angle is more squishy than this draft made it sound: industry league tables differ depending on whether they rank chemical sales, total group sales, or use USD conversions and different segment definitions.

Is It Cheap?

At €19.84, you are paying roughly 9x the midpoint of 2026 EBITDA guidance. BASF’s €22.15 offer at the enterprise value of €14.2 billion implies about 6.7x EBITDA. Both are modest multiples for a specialty chemicals platform with improving margins, which is probably why the board said no. Analysts at DZ Bank rate Evonik a buy with a fair value of €22, emphasizing that beyond financing structure and additional savings potential, the foundation’s stance will ultimately determine the outcome.

The Real Wildcard: RAG-Stiftung

The ultimate outcome will likely depend on the RAG-Stiftung foundation, which says it currently holds a roughly 44% stake in Evonik as part of the assets used to fund Germany’s former hard-coal mining obligations. Any prospective transaction is expected to face close scrutiny around jobs, sites, and long-term industrial strategy.

Whether a deal materializes will depend on whether RAG-Stiftung would reduce its stake and accept BASF shares or a cash payment. RAG-Stiftung has also said its long-term perspective is to reduce the stake to 25.1% over time. Price alone will not close this.

Bull / Base / Bear

Bull: BASF comes back above €24, RAG-Stiftung negotiates employment protections, deal closes. Evonik shareholders collect a 20%+ premium from today’s price.

Base: Talks drag into Q1 2027, BASF improves to €23 to €24, foundation extracts guarantees. Evonik drifts between €20 and €22 in the interim.

Bear: BASF wants synergies that can only be verified through engagement Evonik is refusing to provide. Talks collapse. Evonik retraces toward €18.

Action Plan

The risk/reward at €19.84 is asymmetric but not free. Downside to the pre-bid price is roughly 9%. Upside to a revised deal at €24 is over 20%. If you are sizing a position, enter no more than half now and keep the other half for any dip below €19 if the deal stalls. Set a hard exit if Evonik closes two sessions below €18.50.

Cheap Investor Checklist

• Does BASF formally improve its offer above €22.15?
• Does RAG-Stiftung break its public silence?
• Does Evonik’s 2026 EBITDA land at or above €2.0 billion?
• Do union representatives signal opposition or neutrality?
• Does the spread between €19.84 and €22.15 widen (deal cooling) or narrow (deal warming)?
• Does BASF’s share price stabilize, suggesting its own investors have accepted the acquisition logic?
• Are there competing bidders? No evidence yet, but Dow and LyondellBasell both know Evonik’s portfolio.

Bottom Line

If the board’s “too low” is a negotiating opener and not a final answer, Evonik at €19.84 gives you a real margin of safety before a revised offer. If BASF walks, you own a restructuring-in-progress specialty chemicals business at a fair but not cheap standalone multiple, with 9% of your capital at immediate risk. The position only makes sense if you believe RAG-Stiftung wants a deal at a higher price, not no deal at all.